Should the incorporation of structural alerts be restricted in drug design? an analysis of structure-toxicity trends with aniline-based drugs

Current Medicinal Chemistry

Volumn 22, Issue 4, 2015, Pages 438-464

  Kalgutkar, A S ^a  

^a PFIZER INC   (United States)

Author keywords

Adverse drug reactions; Aniline; Cytochrome P450; Drug; Glutathione; Idiosyncratic; Reactive metabolite

Indexed keywords

AMODIAQUINE; ANILIDE; ANILINE DERIVATIVE; BROMFENAC; CARBAMAZEPINE; CHLORAMBUCIL; CHLORAMPHENICOL; CLOMETACIN; CLOZAPINE; DANTROLENE; FLUTAMIDE; IMINE; KETOCONAZOLE; LAPATINIB; LEFLUNOMIDE; LUMIRACOXIB; NEFAZODONE; NEVIRAPINE; NITROSAMINE; NOMIFENSINE; OXYPHENBUTAZONE; OXYPHENISATINE; PAZOPANIB; PIRPROFEN; PROCAINAMIDE; QUINONE DERIVATIVE; SULFADOXINE; SULFAMETHOXAZOLE; SUNITINIB; UNINDEXED DRUG; DRUG;

ADVERSE DRUG REACTION; ARTICLE; BODY BURDEN; COVALENT BOND; DRUG DESIGN; DRUG DISPOSITION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOXICITY; METABOLITE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; STRUCTURE ACTIVITY RELATION;

ANILINE COMPOUNDS; ANIMALS; DRUG DESIGN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84931263909     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666141112122118     Document Type: Article

References (126)

1. Orr, S. T.; Ripp, S. L.; Ballard, T. E.; Henderson, J. L.; Scott, D. O.; Obach, R. S.; Sun, H.; Kalgutkar, A. S. Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J. Med. Chem., 2012, 55, 4896-4933.
2. Dobo, K. L.; Obach, R. S.; Luffer-Atlas, D.; Bercu, J. P. A strategy for the risk assessment of human genotoxic metabolites. Chem. Res. Toxicol., 2009, 22, 348-356.
3. Guengerich, F. P.; MacDonald, J. S. Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol., 2007, 20, 344-369.
4. Evans, D. C.; Baillie, T. A. Minimizing the potential for metabolic activation as an integral part of drug design. Curr. Opin. Drug Discov. Develop., 2005, 8, 44-50.
5. Park, B. K.; Boobis, A.; Clarke, S.; Goldring, C. E.; Jones, D.; Kenna, J. G.; Lambert, C.; Laverty, H. G.; Naisbitt, D. J.; Nelson, S.; Nicoll-Griffith, D. A.; Obach, R. S.; Routledge, P.; Smith, D. A.; Tweedie, D. J.; Vermeulen, N.; Williams, D. P.; Wilson, I. D.; Baillie, T. A. Managing the challenge of chemically reactive metabolites in drug development. Nat. Rev. Drug Discov., 2011, 10, 292-306.
6. Humphreys, W. G. Overview of strategies for addressing BRIs in drug discovery: Impact on optimization and design. Chem. Biol. Interact., 2011, 192, 56-59.
7. Kalgutkar, A. S.; Gardner, I.; Obach, R. S.; Shaffer, C. L.; Callegari, E.; Henne, K. R.; Mutlib, A. E.; Dalvie, D. K.; Lee, J. S.; Nakai, Y.; O'Donnell, J. P.; Boer, J.; Harriman, S. P. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab., 2005, 6, 161-225.
8. Toranzo, E. G.; Gillesse, T.; Mendenhall, M.; Traiger, G. J.; Riley, P. G.; Hanzlik, R. P.; Wiley, R. A. Effect of substituents on arene oxide-mediated liver toxicity among substituted bromobenzenes. Toxicol. Appl. Pharmacol., 1977, 40, 415-425.
9. Kalgutkar, A. S.; Didiuk, M. T. Structural alerts, reactive metabolites, and protein covalent binding: How reliable are these attributes as predictors of drug toxicity? Chem. Biodivers., 2009, 6, 2115-2137.
10. Kalgutkar, A. S. Handling reactive metabolite positives in drug discovery: what has retrospective structure-toxicity analyses taught us? Chem. Biol. Interact., 2011, 192, 46-55.
11. Stepan, A. F.; Walker, D. P.; Bauman, J.; Price, D. A.; Baillie, T. A.; Kalgutkar, A. S.; Aleo, M. D. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol., 2011, 24, 1345-1410.
12. Salama, A.; Mueller-Eckhardt, C. The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia. N. Engl. J. Med., 1985, 313, 469-474.
13. Yu, J.; Mathisen, D. E.; Burdette, D.; Brown, D. G.; Becker, C.; Aharony, D. Identification of multiple glutathione conjugates of 8-amino-2-methyl-4-phenyl-1, 2, 3, 4-tetrahydroisoquinoline maleate (nomifensine) in liver microsomes and hepatocyte preparations: evidence of the bioactivation of nomifensine. Drug Metab. Dispos., 2010, 38, 46-60.
14. Uetrecht, J. P. Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J. Pharmacol. Exp. Ther., 1985, 232, 420-425.
15. Gardner, I.; Popovic, M.; Zahid, N.; Uetrecht, J. P. A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo. Chem. Res. Toxicol., 2005, 18, 1384-1394.
16. Reilly, T. P.; Lash, L. H.; Doll, M. A.; Hein, D. W.; Woster, P. M.; Svensson, C. K. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J. Invest. Dermatol., 2000, 114, 1164-1173.
17. Callan, H. E.; Jenkins, R. E.; Maggs, J. L.; Lavergne, S. N.; Clarke, S. E.; Naisbitt, D. J.; Park, B. K. Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. Chem. Res. Toxicol., 2009, 22, 937-948.
18. Makarova, S. I. Human N-acetyltransferases and drug-induced hepatotoxicity. Curr. Drug Metab., 2008, 9, 538-545.
19. Wolkenstein, P.; Carriere, V.; Charue, D. A.; Bastuji-Garon, S.; Revuz, J.; Roujeau, J. C.; Beaune, P.; Bagot, M. Slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics, 1995, 5, 255-258.
20. Woosley, R. L.; Drayer, D. E.; Reidenberg, M. M.; Nies, A. S.; Carr, K.; Oates, J. A. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N. Engl. J. Med., 1978, 298, 1157-1159.
21. Cribb, A. E.; Nakamura, H.; Grant, D. M.; Miller, M. A.; Spielberg, S. P. Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism. Biochem. Pharmacol., 1993, 45, 1277-1282.
22. Gross, B. J.; Branchflower, R. V.; Burke, T. R.; Lees, D. E.; Pohl, L. R. Bone marrow toxicity in vitro of chloramphenicol and its metabolites. Toxicol. Appl. Pharmacol., 1982, 64, 557-565.
23. Murray, T.; Yunis, A. A. The cellular uptake and covalent binding of nitroso-chloramphenicol. J. Lab. Clin. Med., 1981, 98, 396-401.
24. Pohl, L. R.; Krishna, G. Study of mechanism of metabolic activation of chloramphenicol by rat liver microsomes. Biochem. Pharmacol., 1978, 27, 335-341.
25. Cravedi, J. P.; Perdu-Durand, E.; Baradat, M.; Alary, J.; Debrauwer, L.; Bories, G. Chloramphenicol oxamylethanolamine as an end product of chloramphenicol metabolism in rat and humans: evidence for the formation of a phospholipid adduct. Chem. Res. Toxicol., 1995, 8, 642-648.
26. Corpet, D. E.; Bories, G. F. [3H]-chloramphenicol metabolism in human volunteer: oxamic acid as a new major metabolite. Drug Metab. Dispos., 1987, 15, 925-927.
27. Arnold, T. H. Jr.; Epps, J. M. 3rd; Cook, H. R.; Hamrick, M. E. Dantrolene sodium: urinary metabolites and hepatotoxicity. Res. Commun. Chem. Pathol. Pharmacol., 1983, 39, 381-398.
28. Neftel, K. A.; Woodtly, W.; Schmid, M.; Frick, P. G.; Fehr, J. Amodiaquine induced agranulocytosis and liver damage. British Med. J., 1986, 292, 721-723.
29. Churchill, F. C.; Patchen, L. C.; Campbell, C. C.; Schwartz, I. K.; Nguyen-Dinh, P.; Dickinson, C. M. Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans.Life Sci., 1985, 36, 53-62.
30. Maggs, J. L.; Tingle, M. D.; Kitteringham, N. R.; Park, B. K. Drugprotein conjugates-XIV. Mechanisms of formation of proteinarylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man.Biochem. Pharmacol., 1988, 37, 303-311.
31. Christie, G.; Breckenridge, A. M.; Park, B. K. Drug-protein conjugates-XVIII. Detection of antibodies towards the antimalarial amodiaquine and its quinone imine metabolite in man and the rat. Biochem. Pharmacol., 1989, 38, 1451-1458.
32. Teng, W. C.; Oh, J. W.; New, L. S.; Wahlin, M. D.; Nelson, S. D.; Ho, H. K.; Chan, E. C. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol. Pharmacol., 2010, 78, 693-703.
33. Mangold, J. B.; Gu, H.; Rodrigues, L. C.; Bonner, J.; Dickson, J.; Rordorf, C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects.Drug Metab. Dispos., 2004, 32, 566-571.
34. Li, Y.; Slatter, G.; Zhang, Z.; Li, Y.; Doss, G. A.; Braun, M. P.; Stearns, R. A.; Dean, D. C.; Baillie, T. A.; Tang, W. In vitro metabolic activation of lumiracoxib in rat and human liver preparations. Drug Metab. Dispos., 2008, 36, 469-473.
35. Kang, P.; Dalvie, D.; Smith, E.; Renner, M. Bioactivation of lumiracoxib by peroxidases and human liver microsomes: identification of multiple quinone imine intermediates and GSH adducts. Chem. Res. Toxicol., 2009, 22, 106-117.
36. Poon, G. K.; Chen, Q.; Teffera, Y.; Ngui, J. S.; Griffin, P. R.; Braun, M. P.; Doss, G. A.; Freeden, C.; Stearns, R. A.; Evans, D. C.; Baillie, T. A.; Tang, W. Bioactivation of diclofenac via benzoquinone imine intermediates-identification of urinary mercapturic acid derivatives in rats and humans. Drug Metab. Dispos., 2001, 29, 1608-1613.
37. Aranda-Michel, J.; Koehler, A.; Bejarano, P. A.; Poulos, J. E.; Luxon, B. A.; Khan, C. M.; Ee, L. C. Nefazodone-induced liver failure: Report of three cases. Ann. Intern. Med., 1999, 130, 285-288.
38. Green D. S.; Barbhaiya, R. H. Clinical pharmacokinetics of nefazodone. Clin. Pharmacokinet., 1997, 33, 260-275.
39. Kalgutkar, A. S.; Vaz, A. D.; Lame, M. E.; Henne, K. R.; Soglia, J.; Zhao, S. X.; Abramov, Y. A.; Lombardo, F.; Collin, C.; Hendsch, Z. S.; Hop, C. E. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab. Dispos., 2005, 33, 243-253.
40. Bauman, J. S.; Frederick, K. S.; Sawant, A.; Walsky, R. L.; Cox, L. M.; Obach, R. S.; Kalgutkar, A. S. Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug. Drug Metab. Dispos., 2008, 36, 1016-1029.
41. Shear, N. H.; Spielberg, S. P. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J. Clin. Invest., 1988, 82, 1826-1832.
42. Maggs, J. L.; Pirmohamed, M.; Kitteringham, N. R.; Park, B. K. Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography/mass spectrometry. Drug Metab. Dispos., 1997, 25, 275-280.
43. Pirmohamed, M.; Kitteringham, N. R.; Guenthner, T. M.; Brekenridge, A. M.; Park, B. K. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem. Pharmacol., 1992, 43, 1675-1682.
44. Spielberg, S. P.; Gordon, G. B.; Blake, D. A.; Mellits, E. D.; Bross, D. S. Anticonvulsant toxicity in vitro: possible role of arene oxides. J. Pharmacol. Exp. Ther., 1981, 217, 386-389.
45. Bu, H. Z.; Zhao, P.; Dalvie, D. K.; Pool, W. F. Identification of primary and sequential bioactivation pathways of carbamazepine in human liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom., 2007, 21, 3317-3322.
46. Bu, H. Z.; Kang, P.; Deese, A. J.; Zhao, P.; Pool, W. F. Human in vitro glutathionyl and protein adducts of carbamazepine-10, 11-epoxide, a stable and pharmacologically active metabolite of carbamazepine. Drug Metab. Dispos., 2005, 33, 1920-1924.
47. Ju, C.; Uetrecht, J. P. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J. Pharmacol. Exp. Ther., 1999, 288, 51-56.
48. Leeder, J. S.; Gaedigk, A.; Lu, X.; Cook, V. A. Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol. Pharmacol., 1996, 49, 234-243.
49. Jorga, K.; Fotteler, B.; Heizmann, P.; Gasser, R. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-Omethyltransferase. Br. J. Clin. Pharmacol., 1999, 48, 513-520.
50. Smith, K. S.; Smith, P. L.; Heady, T. N.; Trugman, J. M.; Harman, W. D.; Macdonald, T. L. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem. Res. Toxicol., 2003, 16, 123-128.
51. Deng, Y.; Madatian, A.; Wire, M. B.; Bowen, C.; Park, J.; Williams, D.; Peng, B.; Schubert, E.; Gorycki, F.; Levy, M.; Gorycki, P. Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human Subjects. Drug Metab. Dispos., 2011, 39, 1734-1746.
52. Patel, S. M.; Johnson, S.; Belknap, S. M.; Chan, J.; Sha, B. E.; Bennett, C. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J. Acquir. Immune Defic. Syndr., 2004, 35, 120-125.
53. Riska, P.; Lamson, M.; MacGregor, T.; Sabo, J.; Hattox, S.; Pav, J.; Keirns, J. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Dispos., 1999, 27, 895-901.
54. Wen, B.; Chen, Y.; Fitch, W. L. Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4.Drug Metab. Dispos., 2009, 37, 1557-1562.
55. Srivastava, A.; Lian, L. Y.; Maggs, J. L.; Chaponda, M.; Pirmohamed, M.; Williams, D. P.; Park, B. K. Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries. Drug Metab. Dispos., 2010, 38, 122-132.
56. Antunes, A. M.; Godinho, A. L.; Martins, I. L.; Justino, G. C.; Beland, F. A.; Marques, M. M. Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine-a possible factor in nevirapine toxicity. Chem. Res. Toxicol., 2010, 23, 888-899.
57. Damsten, M. C.; de Vlieger, J. S.; Niessen, W. M.; Irth, H.; Vermeulen, N. P.; Commandeur, J. N. Trimethoprim: novel reactive intermediates and bioactivation pathways by cytochrome p450s. Chem. Res. Toxicol., 2008, 21, 2181-2187.
58. Lai, W. G.; Zahid, N.; Uetrecht, J. P. Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes. J. Pharmacol. Exp. Ther., 1999, 29, 292-299.
59. Schwartz, D. E.; Vetter, W.; Englert, G. Trimethoprim metabolites in rat, dog and man: Qualitative and quantitative studies. Arzneimittelforschung, 1970, 20, 1867-1871.
60. Liu, Z. C.; Uetrecht, J. P. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J. Pharmacol. Exp. Ther., 1995, 275, 1476-1483.
61. Uetrecht, J. P.; Zahid, N.; Tehim, A.; Fu, J. M.; Rakhit, S. Structural features associated with reactive metabolite formation in clozapine analogues. Chem. Biol. Interact., 1997, 104, 117-129.
62. Maggs, J. L.; Williams, D.; Pirmohamed, M.; Park, B. K. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J. Pharmacol. Exp. Ther., 1995, 275, 1463-1475.
63. Pirmohamed, M.; Williams, D.; Madden, S.; Templeton, E.; Park, B. K. Metabolism and bioactivation of clozapine by human liver in vitro. J. Pharmacol. Exp. Ther., 1995, 272, 984-990.
64. Hart, W.; Stricker, B. H. Flutamide and hepatitis. Ann. Intern. Med., 1989, 110, 943-944.
65. Cetin, M.; Demirci, D.; Unal, A.; Altinbas, M.; Guven, M.; Unluhizarci, K. Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma. Hum. Exp. Toxicol., 1999, 18, 137-140.
66. Schulz, M.; Schmold, A.; Donn, F.; Becker, H. The pharmacokinetics of flutamide and its major metabolites. Eur. J. Clin. Pharmacol., 1988, 34, 633-636.
67. Tevell, A.; Lennernas, H. P.; Jonsson, M.; Norlin, M.; Lennernas, B.; Bondesson, U.; Hedeland, M. Flutamide metabolism in four different species in vitro and identification of flutamide metabolites in human patient urine by high performance liquid chromatography/tandem mass spectrometry. Drug Metab. Dispos., 2006, 34, 984-992.
68. Wen, B.; Coe, K. J.; Rademacher, P.; Fitch, W. L.; Monshouwer, M.; Nelson, S. D. Comparison of in vitro bioactivation of flutamide and its cyano analogue: evidence for reductive activation by human NADPH:cytochrome P450 reductase. Chem. Res. Toxicol., 2008, 21, 2393-2406.
69. Berson, A.; Wolf, C.; Chachaty, C.; Fisch, C.; Fau, D.; Eugene, D.; Loeper, J.; Gauthier, J.-C.; Beaune, P.; Pompon, D.; Maurel, P.; Pessayre, D. Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies. J. Pharmacol. Exp. Ther., 1993, 265, 366-372.
70. Fau, D.; Eugene, D.; Berson, A.; Letteron, P.; Fromenty, B.; Fisch, C.; Pessayre, D. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J. Pharmacol. Exp. Ther., 1994, 269, 954-962.
71. Ichimura, E.; Hara, K.; Matsuzaki, Y.; Doi, M. Improvement of flutamide-induced hepatotoxicity by ursodeoxycholic acid in male rats. Acta Hepatol. Jpn., 1999, 40, 227-234.
72. Kang, P.; Dalvie, D.; Smith, E.; Zhou, S.; Deese, A. Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab. Dispos., 2007, 35, 1081-1088.
73. Soglia, J. R.; Contillo, L. G.; Kalgutkar, A. S.; Zhao, S.; Hop, C. E. C. A.; Boyd, J. G.; Cole, M. J. A semiquantitative method for the determination of reactive metabolite conjugate levels in vitro utilizing liquid-chromatography-tandem mass spectrometry and novel quaternary ammonium glutathione conjugates. Chem. Res. Toxicol., 2006, 19, 480-490.
74. Usui, T.; Mise, M.; Hashizume, T.; Yabuki, M.; Komuro, S. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab. Dispos., 2009, 37, 2383-2392.
75. Geneve, J.; Hayat-Bonan, B.; Labbe, G.; Degott, C.; Letteron, P.; Freneaux, E.; Dinh, T. J.; Larrey, D.; Pessayre, D. Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug.J. Pharmacol. Exp. Ther., 1987, 242, 1133-1137.
76. Egger, H.; Bartlett, F.; Yuan, H.-P.; Karliner, J. Metabolism of pirprofen in man, monkey, rat, and mouse. Drug Metab. Dispos., 1982, 10, 529-536.
77. Kenny, J. R.; Mukadam, S.; Zhang, C.; Tay, S.; Collins, C.; Galetin, A.; Khosjasteh, S. C. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drugdrug interaction. Pharm. Res., 2012, 29, 1960-1976.
78. Rodriguez, R. J.; Buckholz, C. J. Hepatotoxicity of ketoconazole in Sprague-dawley rats: glutathione depletion, flavin-containing monooxygenase-mediated bioactivation and hepatic covalent binding. Xenobiotica, 2003, 33, 429-441.
79. Ciaccio, P. J.; Tew, K. D.; LaCreta, F. P. Enzymatic conjugation of chlorambucil with glutathione by human glutathione S-transferases and inhibition by ethacrynic acid. Biochem. Pharmacol., 1991, 42, 1504-1507.
80. Midskov, C. High-performance liquid chromatographic assay of pyrimethamine, sulfadoxine and its N4-acetyl metabolite in serum and urine after ingestion of Suldox. J. Chromatogr., 1984, 308, 217-227.
81. Dahlin, D. C.; Miwa, G. T.; Lu, A. Y.; Nelson, S. D. N-acetyl-pbenzoquinone imine: A cytochrome P-450-mediated oxidation product of acetaminophen. Proc. Natl. Acad. Sci. USA, 1984, 81, 1327-1331.
82. Mitchell, J. R.; Jollow, D. J.; Potter, W. Z.; Gillette, J. R.; Brodie, B. B. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J. Pharmacol. Exp. Ther., 1973, 187, 211-217.
83. Park, B. K.; Kitteringham, N. R.; Maggs, J. L.; Pirmohamed, M.; Williams, D. P.The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 177-202.
84. Green, J. L.; Heard, K. J.; Reynolds, K. M.; Albert, D. Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: A systematic review and meta analysis. West J. Emerg. Med., 2013, 14, 218-226.
85. Siegers, C. P.; Strubelt, O.; Schütt, A. Proceedings: Hepatotoxicity and metabolism of paracetamol in rats and mice. Naunyn Schmiedebergs Arch. Pharmacol., 1974, 282 (Suppl.), R93.
86. Nakayama, S.; Atsumi, R.; Takakusa, H.; Kobayashi, Y.; Kurihara, A.; Nagai, Y.; Nakai, D.; Okazaki, O. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos., 2009, 37, 1970-1977.
87. Lennernas, H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet., 2003, 42, 1141-1160.
88. Fernandes, N. F.; Martin, R. R.; Schenker, S. Trazodone-induced hepatotoxicity: A case report with comments on drug-induced hepatotoxicity. Am. J. Gastroenterol., 2000, 95, 532-535.
89. Rettman, K. S.; McClintock, C. Hepatotoxicity after short-term trazodone therapy. Ann. Pharmacother., 2001, 35, 1559-1561.
90. Kalgutkar, A. S.; Henne, K. R.; Lame, M. E.; Vaz, A. D. N.; Collin, C.; Soglia, J. R.; Zhao, S. X.; Hop, C. E. C. A. Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem. Biol. Interact., 2005, 155, 10-20.
91. Wen, B.; Ma, L.; Rodrigues, A. D.; Zhu, M. Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab. Dispos., 2008, 36, 841-850.
92. Baiocchi, L.; Frigerio, A.; Giannangeli, M.; Palazzo, G. Basic metabolites of trazodone in humans. Arzeimittelforschung, 1974, 24, 1699-1706.
93. Jauch, R.; Kopitar, Z.; Prox, A.; Zimmer, A. Pharmacokinetics and metabolism of trazodone in man. Arzeimittelforschung, 1976, 26, 2084-2089.
94. Boulton, D. W.; Kollia, G.; Mallikaarjun, S.; Komoroski, B.; Sharma, A.; Kovalick, L. J.; Reeves, R. A. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin. Pharmacokinet., 2008, 47, 475-485.
95. Baldacci, A.; Thormann, W. Analysis of lorazepam and its 3Oglucuronide in human urine by capillary electrophoresis: evidence for the formation of two distinct diastereomeric glucuronides. J. Sep. Sci., 2006, 29, 153-163.
96. Umezawa, H.; Lee, X.-P.; Arima, Y.; Hasegawa, C.; Marumo, A.; Kumazawa, T.; Sato, K. Determination of diazepam and its metabolites in human urine by liquid chromatography/tandem mass spectrometry using a hydrophilic polymer column. Rapid Commun. Mass Spectrom., 2008, 22, 2333-2341.
97. Negrusz, A.; Moore, C. M.; Kern, J. L.; Janicak, P. G.; Strong, M. J.; Levy, N. A. Quantitation of clonazepam and its major metabolite 7-aminoclonazepam in hair. J. Anal. Toxicol., 2000, 24, 614-620.
98. Olivera, M.; Martinez, C.; Gervasini, G.; Carrillo, J. A.; Ramos, S.; Benitez, J.; Garcia-Martin, E.; Agundez, J. A. Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab. Lett., 2007, 1, 3-5.
99. Zhou, H.-H.; Wood, A. J. J. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin. Pharmacol. Ther., 1995, 57, 518-524.
100. Lim, H.-K.; Chen, J.; Sensenhauser, C.; Cook, K.; Subrahmanyam, V. Metabolite identification by data-dependent accurate mass spectrometric analysis at resolving power of 60000 in external calibration mode using an LTQ/orbitrap. Rapid Commun. Mass Spectrom., 2007, 21, 1821-1832.
101. Hagmeyer, K. O.; Stein, J. Hepatotoxicity associated with carvedilol. Ann. Pharmacother., 2001, 35, 1364-1366.
102. Masubuchi, N.; Makino, C.; Murayama, N. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem. Res. Toxicol., 2007, 20, 455-464.
103. Mitchell, J. R.; Potter, W. Z.; Hinson, J. A.; Jollow, D. J. Hepatic necrosis caused by furosemide. Nature, 1974, 251, 508-511.
104. Mitchell, J. R.; Potter, W. Z.; Hinson, J. A.; Jollow, D. J. Furosemide-induced hepatic and renal tubular necrosis I. Effects of treatments which alter drug metabolizing enzymes. Fed. Proc., 1973, 332, 305.
105. Mitchell, J. R.; Snodgrass, W. R.; Gillette, J. R. The role of biotransformation in chemical-induced liver injury. Environ. Health Perspect., 1976, 15, 27-38.
106. Ring, B. J.; Patterson, B. E.; Mitchell, M. I.; Vandenbranden, M.; Gillespie, J.; Bedding, A. W.; Jewell, H.; Payne, C. D.; Forgue, S. T.; Eckstein, J.; Wrighton, S. A.; Phillips, D. L. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo. Clin. Pharmacol. Ther., 2005, 77, 63-75.
107. Fish, D. N.; Chow, A. T. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet., 1997, 32, 101-119.
108. Vance-Bryan, K.; Guay, D. R.; Rotschafer, J. C. Clinical pharmacokinetics of ciprofloxacin. Clin. Pharmacokinet., 1990, 19, 434-461.
109. Abelo, A.; Andersson, T. B.; Antonsson, M.; Naudot, A. K.; Skanberg, I.; Weidolf, L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab. Dispos., 2000, 28, 966-972.
110. Besancon, M.; Simon, A.; Sachs, G.; Shin, J. M. Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J. Biol. Chem., 1997, 272, 22438-22446.
111. Shin, J. M.; Cho, Y. M.; Sachs, G. Chemistry of covalent inhibition of the gastric (H+. K+)-ATPase by proton pump inhibitors. J. Am. Chem. Soc., 2004, 126, 7800-7811.
112. Kosoglou, T.; Statkevich, P.; Johnson-Levonas, A. O.; Paolini, J. F.; Bergman, A. J.; Alton, K. B. Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet., 2005, 44, 467-494.
113. Vanapalli, S. R.; Kambhampati, S. P.; Putcha, L.; Bourne, D. W. A liquid chromatographic method for the simultaneous determination of promethazine and three of its metabolites in plasma using electrochemical and UV detectors. J. Chromatogr. Sci., 2001, 39, 70-72.
114. Nelson, S. D.; Garland, W. A.; Breck, G. D.; Trager, W. F. Quantitation of lidocaine and several metabolites utilizing chemicalionization mass spectrometry and stable isotope labeling. J. Pharm. Sci., 1997, 66, 1180-1190.
115. Devineni, D.; Curtin, C. R.; Polidori, D.; Gutierrez, M. J.; Murphy, J.; Rusch, S.; Rothenberg, P. L. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J. Clin. Pharmacol., 2013, 53, 601-610.
116. Blech, S.; Ludwig-Schwellinger, E.; Gräfe-Mody, E. U.; Withopf, B.; Wagner, K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab. Dispos., 2010, 38, 667-678.
117. Zhang, D.; He, K.; Raghavan, N.; Wang, L.; Mitroka, J.; Maxwell, B. D.; Knabb, R. M.; Frost, C.; Schuster, A.; Hao, F.; Gu, Z.; Humphreys, W. G.; Grossman, S. J. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs and humans. Drug Metab. Dispos., 2009, 37, 1738-1748.
118. Weinz, C.; Schwarz, T.; Kubiza, D.; Mueck, W.; Lang, D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab. Dispos., 2009, 37, 1056-1064.
119. Stangier, J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin. Pharmacokinet., 2008, 47, 285-295.
120. Hoffmann, M.; Kasserra, C.; Reyes, J.; Schafer, P.; Kosek, J.; Capone, L.; Parton, A.; Kim-Kang, H.; Surapaneni, S. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother. Pharmacol., 2013, 71, 489-501.
121. Wang, Z.; Yang, J.; Kirk, C.; Fang, Y.; Alsina, M.; Badros, A.; Papadopoulos, K.; Wong, A.; Woo, T.; Bomba, D.; Li, J.; Infante, J. R. Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab. Dispos., 2013, 41, 230-237.
122. Narasimhan, N. I.; Dorer, D. J.; Niland, K.; Haluska, F.; Sonnichsen, D. Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. J. Clin. Pharmacol., 2013, 38, 440-444.
123. Martin, P.; Oliver, S.; Kennedy, S. J.; Partridge, E.; Hutchison, M.; Clarke, D.; Giles, P. Pharmacokinetics of vandetanib: Three phase I studies in healthy subjects. Clin. Ther., 2012, 34, 221-237.
124. Shamovsky, I.; Ripa, L.; Börjesson, L.; Mee, C.; Nordén, B.; Hansen, P.; Hasselgren, C.; O'Donovan, M.; Sjö, P. Explanation for main features of structure-genotoxicity relationships of aromatic amines by theoretical studies of their activation pathways by CYP1A2. J. Am. Chem. Soc., 2011, 133, 16168-16185.
125. Shamovsky, I.; Ripa, L.; Blomberg, N.; Eriksson, L. A.; Hansen, P.; Mee, C.; Tyrchan, C.; O'Donovan, M.; Sjö, P. Theoretical studies of chemical reactivity of metabolically activated forms of aromatic amines towards DNA. Chem. Res. Toxicol., 2012, 25, 2236-2252.
126. Duckett, D. R.; Cameron, M. D. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin. Drug Metab. Toxicol., 2010, 6, 1175-1193.